Cargando…

Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis

SARS-CoV-2 Omicron variants contain many mutations in its spike receptor-binding domain, the target of all authorized monoclonal antibodies (MAbs). Determining the extent to which Omicron variants reduced MAb susceptibility is critical to preventing and treating COVID-19. We systematically reviewed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Kaiming, Tzou, Philip L., Kosakovsky Pond, Sergei L., Ioannidis, John P. A., Shafer, Robert W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430471/ https://www.ncbi.nlm.nih.gov/pubmed/35700134 http://dx.doi.org/10.1128/spectrum.00926-22

Ejemplares similares

Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons
por: Tzou, Philip L., et al.
Publicado: (2022)

The biological and clinical significance of emerging SARS-CoV-2 variants
por: Tao, Kaiming, et al.
Publicado: (2021)

Sierra SARS-CoV-2 sequence and antiviral resistance analysis program
por: Tzou, Philip L., et al.
Publicado: (2022)

HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing
por: Tao, Kaiming, et al.
Publicado: (2023)

Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy
por: Tzou, Philip L., et al.
Publicado: (2018)

Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
por: Schulz, Sebastian R., et al.
Publicado: (2022)

SARS-CoV-2 Antiviral Therapy
por: Tao, Kaiming, et al.
Publicado: (2021)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
por: Chen, Zhaochun, et al.
Publicado: (2022)

Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences
por: Tzou, Philip L., et al.
Publicado: (2020)

Omicron variant evolution on vaccines and monoclonal antibodies
por: Sabbatucci, Michela, et al.
Publicado: (2023)

Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant
por: Wen, Kun, et al.
Publicado: (2023)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2022)

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages
por: Touret, Franck, et al.
Publicado: (2023)

Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
por: Mazzaferri, Fulvia, et al.
Publicado: (2022)

In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron
por: Hu, Ye-Fan, et al.
Publicado: (2022)

Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys
por: Fenwick, Craig, et al.
Publicado: (2022)

Protection from successive Omicron variants with SARS-CoV-2 vaccine and monoclonal antibodies in kidney transplant recipients
por: Moal, Valérie, et al.
Publicado: (2023)

Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An In Silico Investigation
por: Das, Nabarun Chandra, et al.
Publicado: (2023)

A novel plant‐made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS‐CoV‐2 Omicron variant
por: Jugler, Collin, et al.
Publicado: (2022)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura A., et al.
Publicado: (2022)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura, et al.
Publicado: (2021)

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants
por: Ueno, Mikako, et al.
Publicado: (2022)

Efficacy of anti–SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients
por: Bertrand, Dominique, et al.
Publicado: (2022)

Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants
por: Zheng, Qianqian, et al.
Publicado: (2022)

Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series
por: Fernandes, Guillaume, et al.
Publicado: (2022)

Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron
por: Zhou, Bing, et al.
Publicado: (2022)

Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
por: Manasa, Justen, et al.
Publicado: (2017)

Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2
por: Xie, Jiajia, et al.
Publicado: (2021)

Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
por: Zhou, Hao, et al.
Publicado: (2022)

Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
por: Ong, Chon Phin, et al.
Publicado: (2023)

Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant
por: Błaszczuk, Agata, et al.
Publicado: (2022)

Predicting the mutational drivers of future SARS-CoV-2 variants of concern
por: Maher, M. Cyrus, et al.
Publicado: (2022)

SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
por: Cox, MacGregor, et al.
Publicado: (2022)

Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies
por: Qiu, Hongyu, et al.
Publicado: (2021)

Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2
por: Huang, Kuan-Ying A., et al.
Publicado: (2022)

A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy
por: Meng, Lu, et al.
Publicado: (2023)

The risk of SARS-CoV-2 Omicron variant emergence in low and middle-income countries (LMICs)
por: Bi, Kaiming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6tu7m89gucouqld05at07ln8fc